Clinical Trials – August 4, 2026
Nykode Therapeutics has presented comprehensive preclinical and clinical data on VB10.NEO, its individualized neoantigen therapy (INT), at the Neoantigen Summit in Amsterdam, reinforcing the program as a differentiated platform ready for strategic partnership.
In a new job – August 4, 2026
EQL has recruited Oskar Karmlid as its new Chief Supply Chain Officer (CSCO).
Drug Development Pharma – August 4, 2026
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Lu AH69593, the company’s lead oral orexin 2 receptor agonist and one of several investigational compounds in Lundbeck’s development portfolio for sleep-wake disorders.
In a new job – August 3, 2026
Swedish Orphan Biovitrum has announces that Guido Oelkers has informed the Board of Directors that he has decided to step down as Chief Executive Officer of Sobi to take up another position outside Sobi.
In a new job – August 1, 2026
The Board of Directors has with immediate effect among its members elected Erik Gatenholm to serve as Board Chair of BICO Group AB, until a new Board Chair has been elected by the extraordinary shareholders’ meeting.
Biotech Business – July 31, 2026
Johnson & Johnson has entered a strategic collaboration with Sail Biomedicines to advance in vivo CAR-T therapies for immune-mediated diseases.
Clinical Trials – August 4, 2026
Nykode Therapeutics has presented comprehensive preclinical and clinical data on VB10.NEO, its individualized neoantigen therapy (INT), at the Neoantigen Summit in Amsterdam, reinforcing the program as a differentiated platform ready for strategic partnership.
Clinical Trials – July 14, 2026
Evaxion has presented new data further supporting the multi-component concept of its cytomegalovirus (CMV) vaccine program EVX-V1.
Biotech article – July 13, 2026
BioArctic’s partner Eisai has presented new data at the 2026 Alzheimer’s Association International Conference (AAIC), held in London, July 12-15, demonstrating that the Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) formulation offers efficacy and safety comparable to intravenous (IV) administration in people with early Alzheimer’s disease.
Clinical Trials – June 30, 2026
FluoGuide has announced positive results from the first part of its ongoing FG001-CT-005 Phase 2 trial evaluating FG001 for surgical guidance in patients with oral head and neck cancer.
Clinical Trials – June 23, 2026
Elicera Therapeutics held a scientific advice meeting with the Swedish Medical Products Agency (MPA) regarding the planned first-in-human clinical study of ELC-401, the company’s iTANK-armed CAR T-cell candidate targeting IL13Ra2 in grade IV glioma.
Clinical Trials – June 18, 2026
Cantargia has reported that the first patient has been dosed in a Phase 2 clinical trial investigating nadunolimab in up to 59 current or previous smokers with multifocal high-risk lung nodules, and therefore at risk of developing lung cancer.
PharmaRelations
You will have the opportunity to work in a team of PV specialists, helping our clients with the best solutions depending on their needs. You will work with several clients in parallel giving you great variation in your daily work. You may also have the opportunity to mentor and support other PV consultants within PharmaRelations.
Almirall Nordic
This role combines scientific expertise with a strong commercial mindset and cross-functional collaboration.
Thea Nordic
PharmaRelations is now looking for a Head of Clinical Operations who wants to continue to build up and develop our business in Denmark and South of Sweden (Öresundsregionen).
PharmaRelations
PharmaRelations is now looking for a Head of Clinical Operations who wants to continue to build up and develop our business in Denmark and South of Sweden (Öresundsregionen).
Daiichi Sankyo Nordics
Now, we’re looking for a senior HEOR Manager with a solid HTA toolbox who can help secure and expand access to groundbreaking oncology treatments for patients in the Nordics. You will join Daiichi Sankyo, driven by more than 120 years of innovation and a deep global commitment to improving lives.
PharmaRelations
PharmaRelations is the Nordic Market Leader within Talent services for the Life Science industry. We specialize in partnering with some of the top and most innovative organizations exclusively in the Life Science sector across our region.
In a new job – July 24, 2026
The Board of Directors and the CEO assess that having a consolidated management team on site in Uppsala, close to the core operations, will provide the best conditions for continuing to build the organization required for the next phase and for advancing development programs, the company states.
In a new job – July 15, 2026
Maria Ekdahl brings more than 20 years of senior finance leadership experience, including her current role as CFO of Nasdaq Stockholm-listed pharmaceutical company, Infant Bacterial Therapeutics, and will join Biovica on October 14, 2026.
In a new job – July 11, 2026
CHOSA Oncology has announces the appointment of Bill Cronin to support the company’s commercial expansion in the United States.
Careers article – June 14, 2026
Johnny Mogensen most recently comes from a position as Denmark’s research and innovation attaché in Boston, USA. He has held several positions in the Danish Agency for Higher Education and Science and has also previously been posted to Brussels as an adviser to Denmark’s EU delegation and as a national expert to the European Commission.
Career choice – June 14, 2026
Lionel Leck’s research focuses on pediatric cancer, particularly neuroblastoma – one of the most commonly diagnosed childhood cancers with a poor prognosis.
Careers article – May 5, 2026
BioNTech plans to align and consolidate its manufacturing network further where excess capacity is expected, due to evolving supply needs, mergers and acquisitions, BioNTech’s partners’ manufacturing capacities and completion of contracts, it states. The company plans to exit operations at the manufacturing sites in Idar-Oberstein, Marburg, and Singapore as well as CureVac’s sites, affecting up […]
Europe – July 13, 2026
Spanish biochemist and molecular biologist Salvador Aznar Benitah’s research focuses on how adult stem cells function in normal conditions, aging, and cancer, with particular interest in epigenetics, circadian rhythms, and the mechanisms that allow certain cancer cells to initiate metastasis.
Profiles in Science – April 22, 2026
It’s one thing to “do” physics – but it’s another to explain its fundamentals to others, and the role that physics and other sciences play in their lives.
Profiles in Science – March 23, 2026
Dr. Joanna Rorbach, principal researcher at the Department of Medical Biochemistry and Biophysics at Karolinska Institutet, has been awarded the prestigious Göran Gustafsson Prize by the Royal Swedish Academy of Sciences (Kungliga Vetenskapsakademien).
Global report – July 31, 2026
FedEx has announced the launch of FedEx Life Sciences, a dedicated organization created to support the increasingly complex movement of pharmaceuticals, medical devices, biologics, clinical trials, and other critical healthcare shipments.
Intellectual Property – July 30, 2026
Medivir has received a Notice of Allowance from the US Patent and Trademark Office for its patent application covering the combination of fostroxacitabine bralpamide (fostrox) and lenvatinib in hepatocellular carcinoma and liver metastases.
Pharma Business – July 29, 2026
Pharmability has received approval from the Swedish Medical Products Agency to start a Phase Ib clinical trial of its lead candidate TIR-C in atopic dermatitis, marking the company’s move from preclinical to clinical development.
Europe – July 8, 2026
The new hub marks an investment in software development and clinical expertise and brings together these capabilities to accelerate the path to one intelligent digital ecosystem across the full perioperative workflow.
Legal Advice article – July 7, 2026
VibroSense Dynamics has initiated legal proceedings to address a breach of the exclusive agreement signed with VibroSense’s Chinese distributor Genertec Universal Medical Group Co, a subsidiary of General Technology Holding Co.
Acquisition – July 7, 2026
Asker Healthcare Group has acquired 100% of the shares in Murray Surgical Limited, a distributor of specialist surgical and medical products to the healthcare sector in Ireland.
Biotech Business – July 27, 2026
The Board of Directors of Alligator Bioscience has resolved to discontinue further independent development of mitazalimab and to strategically refocus the company’s resources on the out-licensed HLX22 project.
Biotech article – July 13, 2026
BioArctic’s partner Eisai has presented new data at the 2026 Alzheimer’s Association International Conference (AAIC), held in London, July 12-15, demonstrating that the Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) formulation offers efficacy and safety comparable to intravenous (IV) administration in people with early Alzheimer’s disease.
Biotech Business – July 10, 2026
Biovica has, by mutual agreement, ended the reference laboratory agreement with Tempus AI, announced in May 2025.
Science News – July 31, 2026
Researchers at the University of Turku have developed a new preclinical model that could help accelerate drug development for BAP1-deficient melanomas, a rare and highly aggressive form of melanoma that is resistant to current immunotherapies.
Science News – July 13, 2026
A landmark study led from Lund University has shown that transplanting stem-cell derived dopamine progenitor cells into the brain is feasible. Eight patients were transplanted in the first clinical trial, and no serious side effects directly linked to the transplanted cells were seen during the first year of follow up.
Science News – July 8, 2026
High levels of influenza-specific IgA antibodies in the nasal mucosa are linked to a reduced risk of infection, according to a new study from Danderyd Hospital and SciLifeLab.
This site uses cookies
